Bootcamp is a full-day in-person event designed to support emerging HIV investigators, including faculty at any rank, in developing competitive grant proposals.
Participants submit an aims page in advance and are matched with 6–8 established investigators with expertise in HIV research. During the event, attendees receive rapid, expert feedback through a series of 30-minute, face-to-face "lightning round" consultations. These sessions provide insights to refine proposals and enhance grant competitiveness.
Modeled after the highly successful Dissemination and Implementation Bootcamp at WashU, it aims to build capacity for innovative HIV research.
The 2025 HIV Proposal Bootcamp will be held at the Taylor Avenue Building on the Washington University School of Medicine campus. Accepted proposal teams will have the opportunity to network during meals, consult with HIV research experts, and attend our keynote lecture.
Attendance at this event is by invitation only.
David W. Haas, MD
Keynote speaker:
David W Haas, MD
Professor of Medicine, Vanderbilt University Medical Center
Professor of Pharmacology, Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine
Adjunct Professor of Internal Medicine at Meharry Medical College
As an accomplished HIV clinical trialist and leader in human pharmacogenomic research relevant to HIV infection and its therapy, Dr. David Haas has led the design and implementation of many HIV clinical trials since the early 1990s. In recent years his work has expanded to include pharmacogenomics of anti-tuberculosis therapy. He established and has led the AIDS Clinical Trials Group (ACTG) Clinical Research Site at Vanderbilt since its inception. He has led the ACTG's pharmacogenomics program since 2000, and championed the establishment of the ACTG's Human DNA Repository. His work with the ACTG led to the seminal observation that a frequent CYP2B6 polymorphism predicts delayed clearance of efavirenz, which largely explains increased plasma exposure among individuals of African descent. He is co-PI of a substantial, multidisciplinary R01 entitled "Pharmacogenomics of HIV Therapy." Dr. Haas is highly engaged in multidisciplinary research with an emphasis on the importance of human genomics for antiretroviral and anti-tuberculosis drug disposition, efficacy, and toxicity. He is also associate director of the Tennessee Center for AIDS Research.
More details coming soon!